Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Shots: Witness the journey of the biopharma companies over 20 years with this informative and engaging report. The report highlights the development of the biopharma industry and the key factors influencing them In 2023, JNJ reclaims the topmost position in the list from Pfizer with a revenue of $85.16B, showcasing a sharp 10.30 percent vs…

BySaurabh ChaubeyMay 1, 2024

TOP 20

Top 20 Life Sciences Deals of 2023 by Total Deal Value

Shots: Driven by mutual growth and expansion, strategic collaborations are embedded deeply in the modus operandi of life sciences deals. In 2023, the volume of life science deals was comparatively high vs. 2022 The collaboration deal between Daiichi Sankyo and Merck & Co. for $22B ranks first in our list followed by the development and…

ByPrince GiriFebruary 15, 2024

VIEWPOINTS

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

Shots:Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CTHe also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…

BySenior EditorAugust 17, 2023

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2023

Shots:The first quarter of 2023 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, Selecta and Sobi reported P-III trial (DISSOLVE I & II) results of SEL-212 for chronic refractory goutStarting with the latest acquisitions, Pfizer acquired Seagen for ~$43B. The first quarter of the year also showcases…

BySenior EditorApril 3, 2023

INSIGHTS+

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Shots:The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community The major announcement…

BySenior EditorJanuary 19, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2022

The US FDA approved 1 NDAs and 6 BLA in November 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 73 novel products in 2022In November 2022, the major highlights drugs were Imfinzi (durvalumab) + Imjudo (tremelimumab) approval for metastatic non-small cell lung cancer, Elahere for…

BySenior EditorDecember 15, 2022

VIEWPOINTS

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer

Shots:John spoke about the results from the P-II MOUNTAINEER Trial evaluating its lead candidate in mCRPCHe also talked about TUKYSA (tucatinib) in combination with trastuzumab as a potential treatment for mCRPCThe interview gives a deeper understanding of Seagen’s vision of developing transformative cancer treatment optionsSmriti: Share the details (ROA, MOA & formulations)…

BySenior EditorSeptember 6, 2022

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Top 20 Life Sciences Deals of 2023 by Total Deal Value

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

PharmaShots’ Key Highlights of First Quarter 2023

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Insights+: The US FDA New Drug Approvals in November 2022

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer

Contact US

OUR INFORMATION

FOLLW US

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Top 20 Life Sciences Deals of 2023 by Total Deal Value

Unveiling FDA Acceptance: Ahsan Arozullah of Astellas Dives into Insights on PADCEV sBLAs for UC patients

PharmaShots’ Key Highlights of First Quarter 2023

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas

Insights+: The US FDA New Drug Approvals in November 2022

John Strickler, Associate Professor of Medicine, Duke University School of Medicine, Shares Insights from the P-II Study at the 2022 ESMO World Congress on Gastrointestinal Cancer

FOLLW US

Sign Up to Our Newsletter